The UT Cancer Institute announces its newest, state-of-the-art, cancer treatment facility at 2996 Kate Bond Road, Bartlett, with an open house from 4:30 to 7:30 p.m. on Wednesday, April 6.
The University of Tennessee Cancer Institute announces its newest, state-of-the-art, cancer treatment facility at 2996 Kate Bond Road, Bartlett, with an Open House from 4:30 to 7:30 p.m., Wednesday, April 6.
Offering the latest in clinical research discoveries and new cancer drugs, which are sponsored and funded by the National Cancer Institute, this full-service location brings cutting edge treatment closer to its patients. The Bartlett facility joins the UT Cancer Institute’s network of cancer treatment centers located in Midtown Memphis, East Memphis, Somerville, Forrest City (Ark), Southaven (Miss.) and Grenada (Miss.).
At the Bartlett facility, cancer patients can receive full-service chemotherapy and comprehensive laboratory services, as well as radiation therapy with new Intensity Modulated Radiation Therapy (IMRT) which can deliver higher radiation doses, killing cancer and destroying tumors with fewer side effects. Each center also offers genetic counseling and treatment for hereditary cancers, nutritional support for cancer patients, and cancer education for patients and their families.
The UT Cancer Institute continues to grow its staff of leaders in academic research and clinical treatment with two recent appointments. Raymond Osarogiagbon, MD, known as Dr. Raymond, graduated from the University of Ibadan, Nigeria. He completed his fellowship in hematology oncology at the University of Minnesota and most recently was the Chief of Medical Service for the Amarillo (Texas) Veterans Administration Health Care System. Dr. Raymond has been recognized with the Louise Evans Bruce Award from Texas Tech University and the Outstanding Resident of the Year Award, also from Texas Tech.
Tiffany N. Seagroves, PhD, joined the research staff after completing a Department of Defense Breast Cancer Research Program fellowship at the University of California, San Diego. Prior to that, she held a Susan G. Koman Breast Cancer Foundation fellowship. Dr. Seagroves received her doctorate from Baylor College of Medicine in cell and molecular biology where she was the recipient of several academic honors.
Mohammad Jahanzeb, MD, Van Vleet Endowed Professor of Medical Oncology at UT Health Science Center and interim director of the UT Cancer Institute, said, “The addition of the Bartlett facility and these most recent appointments to our staff move us closer to realizing our dream of taking cancer research to the next level. We’re breaking new ground in our research, and construction recently began on our 90,000 square foot, four-story basic sciences building at the corner of Manassas and Madison. We intend to evolve the UT Cancer Institute into a world-class statewide cancer research entity that will serve the citizens of Tennessee and the Mid-South.”